CAI
Clinical Asset Index
by VOS Supply Group
Drugs · acquisition-cost intelligence

IBU

ibuprofen· ingredient ibuprofenAntiinflammatory preparations, non-steroids for topical use· IBUPROFEN 400 mg/1; IBUPROFEN 600 mg/1; IBUPROFEN 800 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$0.04428
NADAC — pharmacy acquisition cost, not a retail/cash price

Acquisition-cost history

Weekly NADAC per EA — the trend nobody else shows. 6 weeks.

2025-12-172026-05-20

Same-ingredient options by acquisition cost

Other ibuprofen products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.

ProductNADAC / EAvs this
basic care childrens ibuprofen$0.03041−$0.01390
365 whole foods market ibuprofen$0.03227−$0.01200
IBU$0.05051+$0.00620
IBU$0.05674+$0.01250
Advil$0.08009+$0.03580
basic care childrens ibuprofen$0.15408+$0.10980
basic care infants ibuprofen$0.20097+$0.15670

Medicare Part D coverage · CY2026

On 328 plan formularies · typical tier 1
Prior auth 0% · Step therapy 0% · Quantity limit 31% of formularies

Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.